Trials / Completed
CompletedNCT01343966
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 448 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MABT5102A | Repeating subcutaneous injection |
| DRUG | MABT5102A | Repeating intravenous infusion |
| DRUG | placebo | Repeating subcutaneous injection |
| DRUG | placebo | Repeating intravenous infusion |
Timeline
- Start date
- 2011-04-30
- Primary completion
- 2014-02-28
- Completion
- 2014-02-28
- First posted
- 2011-04-28
- Last updated
- 2017-07-12
Locations
92 sites across 6 countries: United States, Canada, France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01343966. Inclusion in this directory is not an endorsement.